GlassScriptPhysician profile
David C Kuhlmann
NPI 1558459925
$3,476.76
in general payments reported to CMS, 2019-2025
13 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.29 · 2020: $1,691 · 2021: $198 · 2022: $163 · 2023: $249 · 2024: $279 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.54 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $2,258.34 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $471.62 | 2019-2025 | |
| Zoll Respicardia, INC. | $226.86 | 2024-2025 | Remede System |
| Axsome Therapeutics, INC. | $174.90 | 2023-2025 | Sunosi |
| Vanda Pharmaceuticals INC. | $73.53 | 2021-2023 | Hetlioz |
| Avadel Cns Pharmaceuticals, LLC | $60.98 | 2025 | |
| Idorsia Pharmaceuticals US INC | $53.41 | 2023-2024 | Quviviq |
| Resmed Corp | $43.66 | 2020-2024 | |
| Inspire Medical Systems, INC. | $42.55 | 2024-2025 | Inspire |
| Eisai INC. | $20.01 | 2021 | |
| Abbott Laboratories | $18.98 | 2022 | |
| Lilly USA, LLC | $16.56 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kuhlmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.